New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
about
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckRationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapyAfatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized cAcquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours.Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.The preoperative platelet-lymphocyte ratio versus neutrophil-lymphocyte ratio: which is better as a prognostic factor in oral squamous cell carcinoma?Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2.Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and TherapyPromising new molecular targeted therapies in head and neck cancer.Afatinib in squamous cell carcinoma of the head and neck.Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer.Emerging drugs for head and neck cancer.Doxorubicin combined with low intensity ultrasound suppresses the growth of oral squamous cell carcinoma in culture and in xenografts.Head and neck squamous cell carcinoma and human papillomavirus: epidemiology, treatment and future trends.Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
P2860
Q33650470-B884272D-9A5F-4E28-AF72-529635655C1BQ33839177-32599A8F-F06E-437E-A585-CFE082925741Q34896542-DD431204-F422-4621-936F-7482B57CAE88Q35275024-22360659-6AED-4A38-8E84-CCAA6FDA98F3Q36371601-71AE7046-A7A6-4B89-8E9D-A66D3F31F81FQ36915015-0DD2B667-90C8-4D3E-9C4A-DE491082170AQ37141350-2806F960-ACA4-417F-99F4-091685BF5215Q37206023-237A90A4-C193-4941-B793-39F639E25393Q37689802-BAEDE9B5-039A-4754-A2AD-424B2280E1CFQ38084617-BA251E9D-023B-4CEB-90D2-18315E1BC054Q38829891-43F05802-3ADF-4B95-863D-9273E12936AEQ39297048-3E6BDACE-22E7-440B-88B6-C5A4D85060A8Q44499046-F3A04D05-2A56-442F-A4DF-5B26A495C63BQ45874449-917A18F8-63B5-47AA-9A69-97FA337D6B4FQ47107703-D8D0EEAC-75C0-4BF1-8F8E-3A91F5DE5172Q48567230-0F551984-F652-4D67-87EB-0A51C5E16659Q49952133-93CD8E9C-CDD9-4F16-BE23-726569C91540Q57818008-5876E158-3AD0-475D-A899-B2E8A0478785
P2860
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
New approaches to EGFR inhibit ...... of the head and neck (SCCHN).
@ast
New approaches to EGFR inhibit ...... of the head and neck (SCCHN).
@en
type
label
New approaches to EGFR inhibit ...... of the head and neck (SCCHN).
@ast
New approaches to EGFR inhibit ...... of the head and neck (SCCHN).
@en
prefLabel
New approaches to EGFR inhibit ...... of the head and neck (SCCHN).
@ast
New approaches to EGFR inhibit ...... of the head and neck (SCCHN).
@en
P2860
P921
P1433
P1476
New approaches to EGFR inhibit ...... of the head and neck (SCCHN).
@en
P2093
Mark Agulnik
P2860
P2888
P304
P356
10.1007/S12032-012-0159-2
P577
2012-01-18T00:00:00Z
2012-12-01T00:00:00Z